Sarah Waheed

3.2k citations

69 papers · 2.0k indexed · h-index 22

Co-authors: Bart Barlogie Frits van Rhee John Crowley Bijay Nair Antje Hoering Yazan Alsayed John D. Shaughnessy Saad Z. Usmani
Topics: Multiple Myeloma Research and Treatments (54 papers)Protein Degradation and Inhibitors (29 papers)Cancer Treatment and Pharmacology (14 papers)
Cited by: Hematology Oncology Genetics
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: United States Iraq China

In The Last Decade

Sarah Waheed

59 papers receiving 2.0k citations

Peers

Countries citing papers authored by Sarah Waheed

Since Specialization

Citations

This map shows the geographic impact of Sarah Waheed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Waheed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Waheed more than expected).

Fields of papers citing papers by Sarah Waheed

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Waheed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Waheed. The network helps show where Sarah Waheed may publish in the future.

Co-authorship network of co-authors of Sarah Waheed

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Waheed. A scholar is included among the top collaborators of Sarah Waheed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Waheed. Sarah Waheed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analysis of the Incidence and Influencing Factors of Depression in the Acute Stage of Ischemic Stroke: A Retrospective Clinical Study 2025 ·Brain and Behavior ·Xiao Zhou,Sarah Waheed,(unknown),(unknown),(unknown),(unknown),Chong Chen,(unknown),Haowei Sun,Ke Cheng,Libo Zhao,(unknown)	1
2	A Narrative Review of Benzo-Fused Coumarins, Shedding Light on Their Medicinal Activities 2023 ·SHILAP Revista de lepidopterología ·Yasser Fakri Mustafa,Sarah Waheed,(unknown),(unknown),(unknown),Omar Qutachi	10
3	AFTER HYDERABAD’S 1948 ANNEXATION: MUSLIM BELONGING AND HISTORIES OF THE LONG PARTITION 2022 ·Asian Affairs ·Sarah Waheed	0
4	Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma 2016 ·Clinical Cancer Research ·James E. McDonald,Marcus M. Kessler,(unknown),Amy Buros,(unknown),Sarah Waheed,Frits van Rhee,Maurizio Zangari,Christoph Heuck,Nathan Petty,Carolina Schinke,Sharmilan Thanendrarajan,Alan Mitchell,Antje Hoering,Bart Barlogie,Gareth J. Morgan,Faith E. Davies	92
5	Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy—Results of a Case Control Study 2016 ·PLoS ONE ·Archana Hinduja,Kaustubh Limaye,Rahul Ravilla,(unknown),Xenofon Papanikolaou,Lai Wei,Michel Torbey,Sarah Waheed	6
6	Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma 2015 ·Leukemia ·Rashid Khan,Senu Apewokin,Monica Grazziutti,Shmuel Yaccoby,Joshua Epstein,Frits van Rhee,Adam Rosenthal,Sarah Waheed,Saad Z. Usmani,Shebli Atrash,(unknown),Antje Hoering,John Crowley,John D. Shaughnessy,Bart Barlogie	40
7	Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Al‐Ola Abdallah,Shebli Atrash,Zainab Shahid,Jameel Muzaffar,Monica Grazziutti,Senu Apewokin,(unknown),(unknown),Sarah Waheed,Frits van Rhee,Christoph Heuck,Donald J. Johann,Bart Barlogie,Saad Z. Usmani	37
8	Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma 2013 ·Haematologica ·Xanthos Papanikolaou,Jackie Szymonifka,Adam Rosenthal,Christoph Heuck,A. Mitchell,Donald J. Johann,Jennifer Keller,Sarah Waheed,Saad Z. Usmani,Frits van Rhee,Clyde Bailey,Nathan Petty,Antje Hoering,John Crowley,Bart Barlogie	10
9	Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single‐agent zoledronic acid 2013 ·British Journal of Haematology ·(unknown),(unknown),Sarah Waheed	0
10	Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 2012 ·Clinical Cancer Research ·Christoph Heuck,Jackie Szymonifka,(unknown),John D. Shaughnessy,Saad Z. Usmani,Frits van Rhee,Elias Anaissie,Bijay Nair,Sarah Waheed,Yazan Alsayed,Nathan Petty,Clyde Bailey,Joshua Epstein,Antje Hoering,John Crowley,Bart Barlogie	13
11	Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data 2012 ·Haematologica ·Sarah Waheed,A. Mitchell,Saad Z. Usmani,Joshua Epstein,Shmuel Yaccoby,Bijay Nair,Rudy Van Hemert,E J Angtuaco,Tracy L. Brown,Twyla B. Bartel,James E. McDonald,E. Anaissie,Frits van Rhee,John Crowley,Barthel Barlogie	52
12	Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? 2012 ·Leukemia ·Saad Z. Usmani,John Crowley,Antje Hoering,Alyson E. Mitchell,Sarah Waheed,Bijay Nair,Yazan Alsayed,(unknown),Bart Barlogie	71
13	Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols 2012 ·Leukemia ·Saad Z. Usmani,Bijay Nair,Pingping Qu,(unknown),(unknown),Nathan Petty,Sarah Waheed,John D. Shaughnessy,Yazan Alsayed,Christoph Heuck,Frits van Rhee,(unknown),Antje Hoering,Jackie Szymonifka,Rachel Sexton,Jeffrey R. Sawyer,Zeba N. Singh,John Crowley,Bart Barlogie	45
14	Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents 2012 ·Haematologica ·Saad Z. Usmani,Christoph Heuck,Alyson E. Mitchell,Jackie Szymonifka,Bijay Nair,Antje Hoering,Yazan Alsayed,Sarah Waheed,Sajjad Haider,Alejandro Restrepo,Frits van Rhee,John Crowley,Bart Barlogie	270
15	Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 2011 ·Blood ·John D. Shaughnessy,Pingping Qu,Saad Z. Usmani,Christoph Heuck,Qing Zhang,Yiming Zhou,Erming Tian,Ichiro Hanamura,Frits van Rhee,Elias Anaissie,Joshua Epstein,Bijay Nair,Owen Stephens,Ryan Williams,Sarah Waheed,Yazan Alsayed,John Crowley,Bart Barlogie	127
16	多発性骨髄腫におけるTotal Therapy 3: 治療の全段階と関連がある,VTD維持成分,ボルテゾミブ,サリドマイド,およびデキサメタゾンの累積用量と早期中断の予後的影響 2010 ·Blood ·(unknown),(unknown),(unknown),(unknown),Sarah Waheed,(unknown),(unknown),(unknown),Antje Hoering,(unknown),(unknown)	2
17	International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols 2010 ·Cancer ·Sarah Waheed,John D. Shaughnessy,Frits van Rhee,Yazan Alsayed,Bijay Nair,Elias Anaissie,Jackie Szymonifka,Antje Hoering,John Crowley,Bart Barlogie	22
18	Improved Outcome with Total Therapy 3 (TT3) In Comparison with Total Therapy 2 (TT2) Can Be Traced to GEP70-Defined High-Risk Disease with Trisomy of 1q21 and Modest but Not Marked Hyper-Activation of the Proteasome Gene PSMD4 2010 ·Blood ·John D. Shaughnessy,Pingping Qu,Erming Tian,Bijay Nair,Sarah Waheed,Yazan Alsayed,Frits van Rhee,John Crowley,Bart Barlogie	3
19	TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3 2009 ·British Journal of Haematology ·John D. Shaughnessy,Yiming Zhou,Jeff Haessler,Frits van Rhee,Elias Anaissie,Bijay Nair,Sarah Waheed,Yazan Alsayed,Joshua Epstein,John Crowley,Bart Barlogie	50
20	Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy 2008 ·Journal of Clinical Oncology ·(unknown),(unknown),(unknown),Mohammad Jahanzeb,Sarah Waheed	7

About Sarah Waheed

Sarah Waheed is a scholar working on Hematology, Genetics and Oncology, having authored 69 papers that have together received 2.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (54 papers), Protein Degradation and Inhibitors (29 papers) and Cancer Treatment and Pharmacology (14 papers). The work is most often cited by research in Hematology (1.7k citations), Oncology (935 citations) and Genetics (219 citations). Sarah Waheed has collaborated with scholars based in United States, Iraq and China. Frequent co-authors include Bart Barlogie, Frits van Rhee, John Crowley, Bijay Nair, Antje Hoering, Yazan Alsayed, John D. Shaughnessy, Saad Z. Usmani, Elias Anaissie and Nathan Petty. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact